Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2007
Headquarters: Franklin Lakes, New Jersey
BD is a global medical technology company operating through three segments: BD Medical (injection, infusion, and surgery products), BD Diagnostics (specimen collection and infectious disease testing), and BD Biosciences (research and clinical tools). The company employs approximately 28,018 people worldwide, with significant operations in the U.S. and international markets including Europe, Asia Pacific, and Latin America.
Key Financial Metrics
Note: Detailed revenue, profit, cash flow, and balance sheet figures are incorporated by reference from the Annual Report to Shareholders (Exhibit 13) and are not explicitly stated in the provided text. The following metrics are available from the filing text:
- Research and Development (R&D) Spend: Approximately $360 million for fiscal 2007 (compared to $302 million in 2006 and $268 million in 2005).
- Acquired In-Process R&D Charges: $122 million in fiscal 2007 related to TriPath and Plasso acquisitions.
- Stock Repurchases (Q3 2007): 490,000 shares purchased under public plans at an average price of $76.92 per share.
- Outstanding Shares: 243,899,512 shares as of October 31, 2007.
- Market Value of Non-Affiliate Stock: Approximately $18.79 billion as of March 30, 2007.
- Valuation Accounts (Trade Receivables): Total allowance for doubtful accounts and cash discounts was $39.65 million as of September 30, 2007.
Material Changes and Operational Highlights
- Acquisitions:
- Completed acquisition of remaining shares of TriPath Imaging, Inc. (93.8%) in December 2006 to advance cancer diagnostics.
- Acquired Plasso Technology, Ltd. in May 2007 for surface-critical research tools.
- Regulatory Compliance: Resolved an FDA warning letter regarding the San Lorenzo, Puerto Rico facility. The FDA re-inspected the facility and found all corrective actions satisfactory, though a formal close-out letter is pending.
- Legal Settlements: Settled the Daniels Sharpsmart antitrust lawsuit on terms not material to the company.
- Executive Changes: Scott P. Bruder appointed Senior Vice President and Chief Technology Officer in September 2007.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: BD's strategy focuses on revenue growth through products delivering greater benefits to patients and researchers. The company anticipates continued investment in R&D, quality management, and productivity. Over half of fiscal 2007 revenues were derived from international operations, exposing the company to foreign currency exchange risks.
Key Risks and Contingencies:
- Legal Proceedings: BD is a defendant in multiple antitrust class actions (consolidated in New Jersey MDL), product liability suits (needlestick injuries, latex gloves), and patent infringement claims (Therasense, Retractable Technologies). The company also faces investigations by the French Judicial Police and U.S. Attorneys General regarding the UN Oil-for-Food Programme and HRDI trade organization participation.
- Regulatory Environment: Extensive regulation by the FDA and foreign agencies impacts product development timelines and costs. Changes in third-party reimbursement policies could negatively affect demand and pricing.
- Supply Chain: Reliance on sole suppliers for certain raw materials (primarily in BD Biosciences) poses a risk of manufacturing interruption.
- Market Dynamics: Intense competition, industry consolidation, and pressure from Group Purchasing Organizations (GPOs) may impact pricing power.
Investor Verification Checklist
- Verify the full consolidated financial statements (Revenue, Net Income, Cash Flow) in Exhibit 13 (Annual Report to Shareholders), as specific totals are not in the main text.
- Review the status of the FDA close-out letter for the San Lorenzo facility to confirm final regulatory clearance.
- Monitor the progress of consolidated antitrust litigation and potential financial exposure from product liability suits.
- Assess the impact of foreign currency fluctuations on international revenue, given that over 50% of sales are outside the U.S.
- Confirm the integration progress and financial performance of the TriPath and Plasso acquisitions.